Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy
DJ Angiolillo, E Bernardo, D Capodanno… - Journal of the American …, 2010 - jacc.org
Objectives: We sought to assess the impact of renal function on platelet reactivity in patients
with diabetes mellitus (DM) and coronary artery disease on aspirin and clopidogrel therapy …
with diabetes mellitus (DM) and coronary artery disease on aspirin and clopidogrel therapy …
In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the …
F Latif, NS Kleiman, DJ Cohen, MJ Pencina… - JACC: Cardiovascular …, 2009 - jacc.org
Objectives: This study sought to evaluate ischemic and bleeding outcomes in patients with
chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI) with …
chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI) with …
Sex-related analysis of short-and long-term clinical outcomes and bleeding among patients treated with primary percutaneous coronary intervention: an evaluation of …
I Mrdovic, L Savic, M Asanin, N Cvetinovic… - Canadian Journal of …, 2013 - Elsevier
Background Unfavourable effect of female sex on short-and long-term clinical outcomes has
been demonstrated in unselected ST-elevation acute myocardial infarction (STEMI) patients; …
been demonstrated in unselected ST-elevation acute myocardial infarction (STEMI) patients; …
Incidence, patterns, and impact of dual antiplatelet therapy cessation among patients with and without chronic kidney disease undergoing percutaneous coronary …
U Baber, SX Li, R Pinnelas, SJ Pocock… - Circulation …, 2018 - Am Heart Assoc
Background—Patients with chronic kidney disease (CKD) experience high rates of ischemic
and bleeding events after percutaneous coronary intervention (PCI), complicating decisions …
and bleeding events after percutaneous coronary intervention (PCI), complicating decisions …
Simple Risk Algorithm to Predict Serious Bleeding in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary …
I Mrdovic, L Savic, G Krljanac, M Asanin, R Lasica… - Circulation …, 2013 - jstage.jst.go.jp
Background: Bleeding is a potentially catastrophic complication after primary percutaneous
coronary intervention (PPCI). It occurs most frequently within the first 30 days following the …
coronary intervention (PPCI). It occurs most frequently within the first 30 days following the …
Long-term percutaneous coronary intervention outcomes of patients with chronic kidney disease in the era of second-generation drug-eluting stents
W Wańha, D Kawecki, T Roleder, A Pluta… - Cardiorenal …, 2017 - karger.com
Abstract Background: The following registry (Katowice-Zabrze retrospective registry) aimed
to assess the influence of a chronic kidney disease (CKD) on long-term clinical outcomes in …
to assess the influence of a chronic kidney disease (CKD) on long-term clinical outcomes in …
[HTML][HTML] Bleeding complications associated with glycoprotein IIb/IIIa inhibitors in patients 80 years of age and older undergoing percutaneous coronary intervention
A Germing, W Bojara, T Lawo, A Ewers… - … & Clinical Cardiology, 2010 - ncbi.nlm.nih.gov
BACKGROUND: Treatment of symptomatic coronary artery disease with percutaneous
intervention requires antithrombotic therapy. Patients with elevated thromboembolic risk …
intervention requires antithrombotic therapy. Patients with elevated thromboembolic risk …
Cost effectiveness of fondaparinux in non-ST-elevation acute coronary syndrome
J Latour-Perez, E de-Miguel-Balsa - Pharmacoeconomics, 2009 - Springer
Background: Fondaparinux has been shown to reduce the risk of major bleeding and 30-day
mortality compared with enoxaparin, in patients with non-ST-elevation acute coronary …
mortality compared with enoxaparin, in patients with non-ST-elevation acute coronary …
Development and validation of a bleeding risk model for patients undergoing elective percutaneous coronary intervention
G Montalescot, G Salette, G Steg, M Cohen… - International journal of …, 2011 - Elsevier
BACKGROUND: Accurate estimation of bleeding risk in patients undergoing elective
percutaneous coronary intervention (PCI) is difficult and not based on widely accepted …
percutaneous coronary intervention (PCI) is difficult and not based on widely accepted …
Impact of renal function on argatroban therapy during percutaneous coronary intervention
MJ Hursting, IK Jang - Journal of thrombosis and thrombolysis, 2010 - Springer
Argatroban, a hepatically metabolized direct thrombin inhibitor, is approved for
anticoagulation in patients with or at risk of heparin-induced thrombocytopenia (HIT) …
anticoagulation in patients with or at risk of heparin-induced thrombocytopenia (HIT) …